From Ethnomedicine to Pharmacological Evidence: Phytochemistry, Biological Activities, and Therapeutic Potential of the Genus Abutilon (Malvaceae)

The genus Abutilon (Malvaceae) comprises taxonomically and phytochemically diverse medicinal plants with a long history of ethnomedicinal use. This critical narrative review integrates evidence on the taxonomy, traditional applications, phytochemical composition, pharmacological activities, molecular mechanisms, safety, and pharmaceutical potential of Abutilon species, incorporating the literature published through September 2026. Flavonoids, phenolic acids, triterpenoids, phytosterols, polysaccharides, and fatty acids represent major reported constituent classes, although the reliability of their identification and quantitative characterization varies among studies. A. indicum and A. theophrasti remain the most extensively investigated species. Experimental findings support preliminary antioxidant, anti-inflammatory, antimicrobial, antidiabetic, hepatoprotective, gastroprotective, and other biological activities, predominantly in biochemical, cellular, and animal models. Mechanistic investigations have reported modulation of NF-κB/MAPK signaling, inflammatory mediators, glucose-regulatory processes, and oxidative stress-related responses; however, direct molecular target validation remains limited. Pharmaceutical studies have explored tablets, phytosomal formulations, and plant-mediated nanoparticles, but evidence of improved systemic bioavailability, therapeutic efficacy, and long-term safety remains insufficient. Toxicological findings indicate preparation- and dose-dependent responses, while controlled clinical evidence is extremely limited. Methodological heterogeneity, incomplete chemical standardization, and limited pharmacokinetic characterization further restrict cross-study comparisons and therapeutic translation. Future research should prioritize authenticated botanical materials, chemically standardized preparations, reproducible dose–response studies, direct mechanistic validation, comprehensive toxicological assessment, and appropriately designed clinical investigations. Overall, Abutilon represents a potentially valuable source of pharmacologically active natural products, but current evidence does not establish standardized clinical applications.